摘要
丙型病毒性肝炎(viral hepatitis type C,HC),系丙型肝炎病毒(HCV)感染所引起的疾病,HCV感染影响着全世界近2亿人群,是引起慢性肝脏疾病的主要病因,进一步会引起肝硬化、肝癌和肝功能衰竭。本文主要介绍HCV及其结构、基于不同靶点的治疗丙肝的药物(标准方案、DAA药物、DAA药物联合标准方案、DAA药物相联合、其他药物联合、HCV疫苗等)的最新研发动态,并对目前的研发现状进行了展望。
Viral hepatitis C （viral hepatitis type C, HC）, is caused by the hepatitis C vires （HCV） , HCV infection affects nearly 200 million people around the world, is the main cause of chronic liver disease, further cause liver cirrhosis, liver cancer and liver failure. Here , this paper introduced the HCV situation and its structure , the latest research and development of dynamic of drags based on different targets for the treatment of hepatitis e （ standard solution, DAA drugs, DAA drugs combined standard solution, DAA phase joint, other drags combined, HCV vaccine, etc. ） , and the present situation of the current research and development is discussed here.
出处
《山东化工》
CAS
2014年第8期42-45,50,共5页
Shandong Chemical Industry
关键词
丙型肝炎病毒
治疗丙肝的药物
DAA药物
研发动态
hepatitis C virus
treatment of hepatitis c drugs
DAA durgs
research and development dynamic
